孟鲁司特联合布地奈德和特布他林与异丙托溴胺雾化吸入治疗小儿喘息性支气管炎的疗效分析

Efficacy analysis of montelukast combined with budesonide and terbutaline and ipratropium in the treatment of asthmatic bronchitis in children

目的探究在小儿喘息性支气管炎治疗中孟鲁司特联合布地奈德、特布他林、异丙托溴胺雾化吸入治疗的临床治疗效果。方法选取2017年3月至2019年2月本院收治的72例喘息性支气管炎患儿,按照随机分组法分为对照组和观察组,每组36例。对照组给予患儿常规治疗方法,观察组患儿给予孟鲁司特联合布地奈德、特布他林、异丙托溴胺雾化吸入治疗方法。比较两组治疗效果。结果观察组症状改善时间低于对照组,观察组IgA、IgG、IgM指标高于对照组,观察组IgE指标低于对照组,观察组临床治疗有效率高于对照组,差异均具有统计学意义(P<0.05)。结论在小儿喘息性支气管炎疾病治疗中应用孟鲁司特联合布地奈德、特布他林、异丙托溴胺雾化吸入治疗方法,能明显缓解患儿的临床症状,提高免疫功能指标,临床治疗效果显著。

Objective To explore the clinical effect of nebulized inhalation of montelukast combined with budesonide, terbutaline and ipratropium in the treatment of asthmatic bronchitis in children. Methods 72 children with asthmatic bronchitis admitted to our hospital from March 2017 to February 2019 were randomly divided into control group and observation group, with 36 cases in each group. The control group was given routine treatment, while the observation group was given nebulized inhalation therapy of montelukast combined with budesonide, terbutaline and ipratropium. The treatment effects were compared between the two groups. Results The duration of symptom improvement in the observation group was lower than that in the control group, the IgA, IgG and IgM indicators in the observation group were higher than those in the control group, the IgE indicators in the observation group were lower than those in the control group, and the clinical treatment efficiency in the observation group was higher than that in the control group, with statistically significant difference(P<0.05). Conclusion The treatment of asthmatic bronchitis in children with montelukast combined with budesonide, terbutaline and ipratropium by inhalation can significantly relieve the clinical symptoms of children, improve the indicators of immune function, and the clinical treatment effect is significant.